What to know about progress for 154-home North Nashville development
The $95 million project, called "The Lanes," is one of the largest private developments in the neighborhood and abuts the eastern-most section of Tennessee State University's campus. The primary address of the development is 2500 W Heiman St.
The project is spearheaded by local developers Edward Tinsley, Jared Bradley and Eric Russell. Tinsley and Bradley have worked on other Nashville developments together in recent years, and Russell is principal at Big Plan Holdings, a real estate development firm that launched in 2020. The team purchased the 12-acre property in 2022 and began construction last year.
Thoughtful neighborhood design was a priority for the development team, which spent time planning how the property would contribute to the overall neighborhood -- including with upgraded sidewalks, street parking and other infrastructure surrounding the site.
"We want the front porch of this project to be something that's beautiful for the neighborhood," Tinsley said.
The plot of land was previously owned by a different development team with plans for a more dense, multifamily project. An LLC tied to Tinsley, Bradley and Russell purchased the land in December 2022 for $7.7 million. The team worked with Metro Nashville to get the land rezoned to allow for the single family subdivision.
The single family homes will be priced between $690,000 and $800,000 to start and include a range of three- to-four-bedroom floorplans. In addition to the 154 homes, the project will consist of a clubhouse with spa-like amenities like saunas and cold plunge tubs. A fitness center, resort-style pool, coworking space, community garden and one-mile walking path will also be included.
A railroad borders the eastern side of the parcel, and the developers plan to add a greenway along it, connecting Heiman Street to a route that could eventually lead along the tracks to the Ted Rhodes Golf Course and Cumberland River Greenway, Tinsley said.
Each home will be move-in ready, complete with custom interior design by Nashville-based firm Murphy Maude Interiors.
"We've taken a lot of care to make it feel like you're stepping into a high-design place," said Leslie Murphy, founder of Murphy Maude.
This article originally appeared on Nashville Tennessean: Development project adds 154 homes to Nashville neighborhood
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Why Casella Waste Systems Stock Flopped on Friday
Key Points The company's bottom-line miss in its second quarter was striking. That was compounded by a guidance reduction for full-year profitability. 10 stocks we like better than Casella Waste Systems › Solid waste and recycling management company Casella Waste Systems (NASDAQ: CWST) was surely eager to start its weekend. On Friday, the company published quarterly results that were a dud with investors, who sent its share price down by more than 5%. That was more deeply in the red than the S&P 500 index's 1.6% dive. One big whiff Much of this was because of a fairly wide bottom-line miss in Casella's second quarter, the results of which were published after market close Thursday. In the quarter, Casella booked revenue of over $465 million. So far, so good, as this was more than 23% higher than in the same quarter of 2024. Further down the profit and loss statement, however, the company revealed that its generally accepted accounting principles (GAAP) net income fell to $5.2 million ($0.08 per share) from the year-ago profit of slightly over $7 million. That drop was discouraging enough, but it was exacerbated by the fact that analysts were expecting far better from the company. On average, they were modeling $0.33 per share for bottom-line profitability, although they underestimated revenue with a collective $454 million projection. Acquisitions played a role in Casella's top-line growth, as the company completed six buyouts across the first half of this year. Management also said higher landfill volumes were a catalyst. Notable guidance revisions Outside of the bottom-line miss, Casella's change in guidance was dismaying for investors. Although it raised its outlook for full-year 2025 revenue -- $1.82 billion to $1.84 billion from just under $1.78 billion to a bit over $1.8 billion -- it cut that for profitability. The company now believes its GAAP net income will land at $8 million to $18 million; the previous guidance called for $10 million to $25 million. Should you buy stock in Casella Waste Systems right now? Before you buy stock in Casella Waste Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casella Waste Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Casella Waste Systems Stock Flopped on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data